ATRA ATARA BIOTHERAPEUTICS INC US FDA Inspections 8-K Filing 2024 - FDA Acceptance and Priority Review of Biologics License Application for Tabelecleucel Atara Biotherapeutics announced that the FDA has accepted for priority review their Biologics License Application for tabelecleucel for the treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease.Get access to all SEC 8-K filings of the ATARA BIOTHERAPEUTICS INC